Why Joby Aviation's Move Into Defense Is a Bullish Sign for Investors

Joby Aviation plans to acquire defense-tech company Resonant Sciences for $500 million ($450 million cash and $50 million in common stock), moving further into defense. Resonant generated more than $100 million in trailing revenue with ~40% year-over-year growth, which Joby says will diversify revenue (after Blade made up >90% of current revenue) and strengthen autonomous defense systems. The deal is expected to be expensive near term, but it sparked only a short-term pullback as investors weigh longer-term defense credibility against Joby’s already-volatile, down >50% over 12 months, and regulatory hurdles for air taxis.

Analysis

The strategic read is less about a single deal and more about JOBY trying to escape a binary, regulation-bound equity story by adding a cash-generating defense leg. That can matter for valuation: if defense revenue is sticky and contract-backed, the market may start to price JOBY as a hybrid autonomy platform rather than a pure pre-commercial eVTOL optionality bet. The first-order benefit is lower perceived financing risk; the second-order benefit is that defense credibility can improve supplier access, hiring, and program win-rate across autonomous systems.

The market may be underestimating how much the deal changes the probability distribution, but it may be overestimating near-term accretion. A cash-heavy acquisition likely keeps dilution and integration risk front and center for the next 1-3 quarters, while defense revenue itself is usually lumpy and lower-multiple than software-like narratives imply. The key question is whether Resonant meaningfully extends runway and cross-sells into larger programs, or whether JOBY simply swaps one speculative growth stream for another at a premium multiple.

Relative value matters more than absolute value here. If investors want exposure to a de-risking autonomy stack, JOBY now has a stronger defense angle than pure-play eVTOL peers like ACHR, but the cleaner long-duration beneficiaries may still be defense autonomy names such as KTOS/AVAV if this signals broader procurement appetite. Falsifiers: pro forma cash burn rising faster than expected, no disclosed backlog/contract durability, or any indication that the transaction forces additional equity issuance within the next 6-12 months.

Key Decisions for Investors

• Tactically buy JOBY only on post-deal weakness over the next 1-3 months, but keep size small until management discloses pro forma cash runway and integration targets; the thesis dies if dilution or burn accelerates.
• Run a relative-value trade: long JOBY / short ACHR for 1-3 months to express the view that defense diversification lowers JOBY’s financing risk premium versus a pure eVTOL peer.
• Use KTOS or AVAV as cleaner 6-12 month beneficiaries if the acquisition proves defense autonomy demand is real; these names have less balance-sheet and certification optionality risk than JOBY.
• Do not buy the stock on the assumption the defense business is immediately value-accretive; wait for evidence of backlog quality and contract renewal cadence, or treat the move as a watchlist item only.